UPLOAD Filing
Shuttle Pharmaceuticals Holdings, Inc.
Date: Aug. 8, 2025 · CIK: 0001757499 · Accession: 0000000000-25-008341
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289231
Letter
Re: Shuttle Pharmaceuticals Holdings, Inc. Registration Statement on Form S-1 Filed August 5, 2025 File No. 333-289231 Dear Christopher Cooper:
August 8, 2025
Christopher Cooper Interim Chief Executive Officer Shuttle Pharmaceuticals Holdings, Inc. 401 Professional Drive, Suite 260 Gaithersburg, MD 20879
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jeff Cahlon, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> August 8, 2025 Christopher Cooper Interim Chief Executive Officer Shuttle Pharmaceuticals Holdings, Inc. 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 Re: Shuttle Pharmaceuticals Holdings, Inc. Registration Statement on Form S-1 Filed August 5, 2025 File No. 333-289231 Dear Christopher Cooper: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeff Cahlon, Esq. </TEXT> </DOCUMENT>